Loading patent…
AssigneesBiogen, Inc., University of California
InventorsJeffrey L. Browning, Carl F. Ware
Estimating the term…
This invention relates to lymphotoxin-β, a lymphocyte membrane type protein. This protein is found on the surface of a number of cells, including phorbol ester (PMA) stimulated T cell hybridoma II-23.D7 cells. This invention also relates to complexes formed between lymphotoxin-β and other peptides such as lymphotoxin-α and to complexes comprising multiple subunits of lymphotoxin-β. These proteins and complexes are useful in holding LT-α formed within the cell on the cell surface where the LT-α/LT-β complex may act as an inflammation regulating agent, a tumor growth inhibiting agent, a T cell inhibiting agent, a T cell activating agent, an autoimmune disease regulating agent, or an HIV inhibiting agent. Furthermore, the antitumor activity of the LT-α/LT-β complex may be delivered to tumor cells by tumor infiltrating lymphocytes (TILs) transfected with the gene for LT-β.
Lymphotoxin-β, a lymphocyte membrane-type polypeptide comprising SEQ ID NO:2.
A soluble lymphotoxin-13 peptide comprising an amino acid sequence selected from the group consisting of:
A polypeptide comprising an amino acid sequence that is encoded by a DNA from the group consisting of:
A polypeptide comprising an amino acid sequence that is encoded by a DNA from the group consisting of:
An engineered polypeptide comprising the amino acid sequence defined by SEQ ID NO:2 wherein the sequence Leu Gly Leu is cleaved from the 5′ end of said sequence and replaced by a single Met or Leu residue.
An isolated DNA sequence selected from the group consisting of:
An engineered DNA sequence comprising the nucleotide sequence defined by SEQ ID NO:1 wherein the nucleotides CTGGGGCTG are cleaved from the 5′ end of said sequence and replaced by a single start codon.
A polypeptide complex comprising a plurality of lymphotoxin-β polypeptide units.
A nucleotide sequence coding for lymphotoxin-β comprising the nucleotide sequence represented by SEQ ID NO:1 and further comprising an engineered nucleotide sequence at the 5′ end wherein said engineered sequence comprises a functional start codon that is either ATG or CTG and wherein any other codon within said engineered sequence coding for leucine is not CTG.
Dependencies are inferred from the claim text.